A canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 13, Issue 1, 1993, Pages 25-40

  Chouinard, Guy ^a   Jones, Barry ^c   Remington, Gary ^d   Bloom, David ^b   Addington, Donald ^f   Macewan, G William ^g   Labelle, Alain ^c   Beauclair, Linda ^a   Arnott, Wendy ^e  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e Janssen Pharmaceutica   (Canada)

^f FOOTHILLS HOSPITAL   (Canada)

^g RIVERVIEW HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; RISPERIDONE;

ADULT; AGITATION; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMAN; ISOXAZOLES; MALE; MIDDLE AGE; NEUROLOGIC EXAMINATION; PIPERIDINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0027475985     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/00004714-199302000-00004     Document Type: Article

References (52)

1. Antipsychotic agents. In: Baldessarini RJ, ed. Chemotherapy in psychiatry: principles and practice. Cambridge, MA: Harvard University Press, 1985:14–92.
2. National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964;10:246–61.
3. Kane JM. Somatic therapy. In: Frances AJ, Hales RE, eds. Psychiatry update: American Psychiatric Association annual review. Vol. 5. Washington, D.C.: American Psychiatric Press, 1986:78–95.
4. Kay SR, Singh MM. The positive-negative distinction in drug-free schizophrenic patients: stability, response to neuroleptics, and prognostic significance. Arch Gen Psychiatry 1989;46:711–8.
5. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine: discussion 2. Br J Psychiatry 1980;137:383–6.
6. Rifkin A, Quitkin F, Klein D. Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 1975;32:672–4.
7. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987;48(suppl 9):13–9.
8. Gelenberg AJ, Mandel MR. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 1977;34:947–50.
9. Leff JP, Wing JK. Trial maintenance therapy in schizophrenia. BMJ 1971;2:599–603.
10. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987;13:133–56.
11. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health: longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991;48:239–46.
12. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophr Res 1990;5:21–33.
13. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8:21S–26S.
14. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986;22:254–8.
15. Niemegeers CJE, Leysen JE. The pharmacological and biochemical basis of neuroleptic treatment in schizophrenia. Pharm Weekbl [Sci] 1982;4:71–8.
16. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133–52.
17. Carisson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179–86.
18. Crow TJ. Molecular pathology of schizophrenia more than one disease process? BMJ 1980;280:66–8.
19. Waldmeier PC. Serotonergic modulation of mesolimbic and frontal cortical dopamine neurons. Experentia 1980;36:1092–4.
20. Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM. Serotonergic component of neuroleptic receptors. Nature (Lond) 1978;272:168–71.
21. Ceulemans DLS, Gelders YG, Hoppenbrouwers ML, Reyntjens AJM, Janssen PAJ. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 1985;85:329–32.
22. 2 receptor blocker. Drug Dev Res 1986;8:205–11.
23. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685–93.
24. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.
25. Megens AAHP, Awouters FHL, Niemegeers CJE. Differential effects of the new antipsychotic risperldone on large and small motor movements in rats. Psychopharmacology 1988;95:493–6.
26. Meert TF, de Haes P, Niemegeers CJE. Risperidone (R64766), a potent and complete LSD-antagonist in drug discrimination by rats. Psychopharmacology 1989;97:206–12.
27. Roose K, Gelders YG, Heylen S. Risperidone (R64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg 1988;88:233–41.
28. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1989;99:445–9.
29. 2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose finding study. Schizophr Res 1989;2:411–5.
30. Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 1989;46:876–83.
31. t antagonism in schizophrenia: clinical, extrapyramidal and neuroendrocrine response in a preliminary study with risperidone. Hum Psychopharmacol 1990;5:225–31.
32. Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989;155(suppl 5):33–6.
33. Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJ, Janssen PAJ. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990;23:206–11.
34. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition, revised. Washington, DC: American Psychiatric Association, 1987.
35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
36. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99–110.
37. Guy W, ed. ECDEU Assessment manual for psychopharmacology revised. Rockville, MD: National Institute of Mental Health, 1976; DHEW publication no. (ADM) 76–338.
38. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 1979;40:147–52.
39. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extra-pyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
40. Chouinard G, Ross-Chouinard A, Gauthier S, Annable L, Mercier P. An extrapyramidal rating scale for idiopathic and neuroleptic-induced parkinsonism and dyskinesia. Collegium Internationale Neuro-Psychopharmacologicum, 14th C.I.N.P Congress, Florence Italy, June 19-23, 1984, p. 16.
41. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scand 1987;76(suppl 334):1–100.
42. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.
43. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–7.
44. Klieser E, Lehmann E. Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Neuropsychobiology 1987;18:122–6.
45. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79–90.
46. Van Putten T, Marder SR, Mintz J. The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharmacol Bull 1987;23:201–5.
47. Van Putten T, Marder S, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754–8.
48. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739–45.
49. Davis JM, Erickson S, Dekirmenjian H. Plasma levels of antipsychotic drugs and clinical response. In: Lipton MA, DiMascio A, Killam KF, eds. Psychopharmacology: a generation of progress. New York: Raven Press, 1978:905–15.
50. Miller R, Wickens JR, Beninger RJ. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Prog Neurobiol 1990;34:143–83.
51. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin, pKi values. J Pharmacol Exp Ther 1989;251:238–46.
52. 2 sites in rabbit cerebral cortex and neostriatum. Neurochem Res 1990;15:507–14.